Acelyrin (SLRN) Adopts Limited-Duration Stockholder Rights Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
ACELYRIN Adopts Limited-Duration Stockholder Rights Plan
March 13, 2025 7:00 AM EDTLOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners continued rapid accumulation of 8.8% of ACELYRINS outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan (Rights Plan).
The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value.
Pursuant to the Rights Plan, the Company is... More
